Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Small molecule inhibitors of PARP1/2 such as olaparib have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations. Indeed, in clinical trials PARP1/2 inhibitors elicit sustained anti-tumor responses in patients with germ-line BRCA gene mutations. In hyp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Bajrami, Ilirjana, Frankum, Jessica R., Konde, Asha, Miller, Rowan E., Rehman, Farah L., Brough, Rachel, Campbell, James, Sims, David, Rafiq, Rumana, Hooper, Sean, Chen, Lina, Kozarewa, Iwanka, Assiotis, Ioannis, Fenwick, Kerry, Natrajan, Rachael, Lord, Christopher J., Ashworth, Alan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886090/
https://ncbi.nlm.nih.gov/pubmed/24240700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2541
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi